Procedures
malaria, parasitaemia, viral hepatitis
MALARIA, BLOOD, VIRAL HEPATITIS, ADVERSE EVENT
Screening procedures included physical examination, medical history, 12-lead electrocardiogram (ECG), vital signs, clinical laboratory tests, viral hepatitis serology, and a pregnancy test. Patients were hospitalized for at least the first 48 h following treatment administration and longer if malaria symptoms or parasitaemia persisted. Patients were followed up on Days 3, 4, 5, 6, 7, 10, 14, 21 and 28. All patients received definitive approved anti-malarial treatment on Day 29 if they had not already received rescue therapy.Blood samples for parasite assessments were taken at screening, every 6 h until 36 h post-dose, at hours 48, 72, 96, 120, 144, and 168 post-dose, on Days 10, 14, 21, and 28, and at any time if clinically indicated. Giemsa-stained thick and thin blood films were prepared, and parasites identified and enumerated independently by two trained microscopists using standard procedures [Adverse events were assessed throughout the study. Additional post-treatment safety assessments were 12-lead ECGs, vital signs, haematology, and clinical laboratory tests (Additional file Blood samples were taken pre- and post-dose for PK assessments of artefenomel (12 sample time points) and ferroquine (11 sample time points) (Additional file 